<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="infection with the hepatitis B virus are lamivudine, adefovir, telbivudine," exact="tenofovir" post="and entecavir. One mutation, called the YMDD motive, is"/>
 <result pre="now has been replaced by other more potent antivirals, like" exact="entecavir" post="and tenofovir. Entecavir, however, is less effective in patients"/>
 <result pre="is less effective in patients who have been pretreated with" exact="lamivudine" post="and who carry the YMDD variant of hepatitis B."/>
 <result pre="assay, but sequence-based assays have also been developed. First-generation protease-inhibitors" exact="telaprevir" post="and boceprevir are active against hepatitis C genotype 1,"/>
 <result pre="sequence-based assays have also been developed. First-generation protease-inhibitors telaprevir and" exact="boceprevir" post="are active against hepatitis C genotype 1, but they"/>
 <result pre="patients that receive treatment with acyclovir, or similar medications like" exact="valaciclovir" post="and famciclovir, become resistant. Up to 95% of resistance"/>
 <result pre="in UL54 are associated with higher levels of resistance to" exact="ganciclovir" post="or cross-resistance to cidofovir or foscarnet. Influenza Virus Influenza"/>
 <result pre="with higher levels of resistance to ganciclovir or cross-resistance to" exact="cidofovir" post="or foscarnet. Influenza Virus Influenza is a member of"/>
 <result pre="treatment. Most influenza A and B strains are sensitive to" exact="oseltamivir" post="and zanamivir, two neuraminidase inhibitors. Occasionally, resistant strains are"/>
 <result pre="long-term treatment of influenza infection in immunocompromised patients. Resistance to" exact="oseltamivir" post="has also been reported during the 2007â€“2008-winter season, due"/>
</results>
